产品描述
| 沸点 | ~653.7 °C at 760 mmHg |
| 折光率 | 1.63 |
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
| 密度 | 1.4000 |
| 应用 | A potent and selective inhibitor of Raf-B protein kinase carrying V600E mutation |
| 产品介绍 | Dabrafenib (达拉菲尼; GSK2118436)是高活性BRAFV600特异性抑制剂，IC50为0.8 nM，比对野生型B-Raf和c-Raf的抑制性高4倍和6倍。 |
| 备注 | Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3. |
| 生化机理 |
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. |
| 别名 | 达拉菲尼;GSK-2118436A; GSK-2118436; GSK2118436A; GSK2118436A; GSK 2118436; GSK 2118436; N-(3-(5-(2-氨基-4-嘧啶基)-2-(叔丁基)-4-噻唑基)-2-氟苯基)-2,6-二氟苯磺酰胺;;GSK-2118436A;GSK-2118436;GSK2118436A;GSK2118436A;GSK 2118436;GSK 2118436;n-(3-(5-(2-amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide |
